Pharmocann
Medical Cannabis Cultivation and R&D
Company Overview
Snapshot
Founded in April 2008, Pharmocann operates with 1–10 employees. The company has raised $690K across one funding round from one investor. In December 2018, Pharmocann became publicly listed on the TASE.
Business overview
Pharmocann specializes in the development and production of medical cannabis, cultivating various strains in hothouses located in the Jezreel Valley, Galilee. The company's operations encompass cultivation, harvesting, and production, alongside research and development for new cannabis strains. Pharmocann also develops medical marijuana cultivation centers and dispensaries, offering a product line that includes oils, ointments, tablets, inhalers, suppositories, and pre-rolled cigarettes. Through strategic partnerships with medical cannabis labs, Pharmocann produces standardized, GMP-manufactured products, serving over 3,000 patients monthly and yielding approximately two tons of medical cannabis annually. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Cannabis and Ag Tech.
Strategic signal
In November 2021, Pharmocann announced a collaboration with Shamir Institute to research 'magic mushrooms,' signaling a strategic expansion beyond traditional cannabis products into the broader psychedelics market. This move indicates the company's intent to diversify its therapeutic offerings and explore new frontiers in plant-based medicine, potentially opening new revenue streams and positioning Pharmocann at the forefront of emerging medical treatments.
Log in to access full profile ›Company Intelligence Q&A
- When did Pharmocann go public?
- Pharmocann went public on TASE in December 2018.
- What was a significant partnership for Pharmocann in 2021?
- In November 2021, Pharmocann teamed up with Shamir Institute to research magic mushrooms, indicating an expansion into new therapeutic areas.
- What was the latest development regarding Pharmocann's production capacity?
- In April 2022, Pharmocann announced an expansion of its production capacity.
- What was a notable event concerning Pharmocann's cannabis production in July 2022?
- In July 2022, a fungus infiltrated Pharmocann's cannabis crops, leading to the unexpected departure of the CEO.
- What was the outcome of Pharmocann's stock offering in September 2022?
- In September 2022, Pharmocann issued shares at end-of-season prices, resulting in a 27% drop in its stock.